Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Top tierTRYNGOLZA is approved in the United States, or U.S., as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome, or FCS, and is approved in the European Union, or EU, for patients with genetically confirmed FCS. TRYNGOLZA is also approved in Canada. TRYNGOLZA is the first-ever FDA-approved treatment that significantly and substantially reduces triglyceride levels in adults with FCS and provides clinically meaningful reduction in acute pancreatitis, or AP, events when used with an appropriate diet (≤20 grams of fat per day).
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Business segments
Q2 2026 · $275.8MThe company’s own SEC segment disclosure.
- Royalty$76.0M28%
- Spinraza Royalties$53.5M19%
- Salanersen$45.0M16%
- DAWNZERA Sales$26.6M10%
- Sapablursen$20.0M7%
- Wainus Royalties$16.4M6%
- Other (4)$38.3M14%
Ionis Pharmaceuticals, Inc. (IONS) reported revenue of $268M in Q2 2026 (quarter ended June 30, 2026), down 41% from the same quarter a year earlier. That came with a gross margin of 99% and net loss of $115M. For the full year FY2025, revenue was $944M (+34% year on year) and net income −$381M. Its largest product in 2026-Q2 was Royalty at $76M, 28% of the disclosed total, just ahead of Spinraza Royalties at 19%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.